Alex Zisson

Biography

    Alex joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics and Keystone Dental.  Prior to H.I.G., Alex spent 13 years at Thomas, McNerney & Partners.  Previous board seats included Auspex Pharmaceuticals (sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services and Coley Pharmaceutical (sold to Pfizer).  Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan).  Alex is the co-chair of the Business Advisory Council of the Children's Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs.  He is also a board member for the Greenwich Council of the Boy Scouts of America. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.

Research Interest

  Clinical Investigation